ARS Pharmaceuticals, Inc. (SPRY) — Financial statements
Income statement, balance sheet, and cash flow for ARS Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 84↓5.5% | 89↑297063.3% | 0.03↓97.7% | 1↓76.1% | 6 | |
| Cost of Revenue | 20↓0.7% | 21 | 0.00↓100.0% | 17↑7937.6% | 0.21 | |
| Gross Profit | 64↓6.9% | 69↑228540.0% | 0.03↑100.2% | -16↓398.6% | 5 | |
| Operating Expenses | ||||||
| R&D Expenses | 13↓32.7% | 20↓3.4% | 20↑10.3% | 18↓9.4% | 20 | |
| General & Administrative Expenses | 0.00 | 0.00↓100.0% | 47↑156.2% | 18↑293.8% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00↓100.0% | 0.20 | 0.00 | |
| SG&A Expenses | 230 | 0.00↓100.0% | 47↑153.5% | 19↑298.0% | 5 | |
| Other Expenses | 0.00↓100.0% | 52 | 0.00↑100.0% | -17↓8031.5% | -0.21 | |
| Operating Expenses | 243↑239.5% | 72↑6.1% | 68↑242.7% | 20↓20.3% | 25 | |
| Total Costs & Expenses | 264↑185.9% | 92↑36.5% | 68↑83.4% | 37↑47.6% | 25 | |
| Operating Results | ||||||
| Operating Income | -179↓5720.6% | -3↑95.4% | -68↓90.1% | -36↓82.6% | -19 | |
| Depreciation & Amortization | 1↑1630.4% | 0.08↑8.2% | 0.07↓77.1% | 0.32↑49.8% | 0.21 | |
| EBITDA | -178↓5828.1% | -3↑95.5% | -67↓91.6% | -35↓82.9% | -19 | |
| EBIT | -179↓5720.6% | -3↑95.4% | -68↓90.1% | -36↓82.6% | -19 | |
| Interest & Other Income | ||||||
| Net Interest Income | 8 | 0.00 | 0.00 | 0.00↓100.0% | 0.69 | |
| Interest Income | 11 | 0.00 | 0.00 | 0.00↓100.0% | 0.80 | |
| Interest Expense | 3 | 0.00 | 0.00 | 0.00↓100.0% | 0.11 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 8↓29.0% | 11↓13.6% | 13↑1477.3% | 0.83↑205.7% | -0.79 | |
| Income Before Tax | -171↓2168.3% | 8↑115.2% | -54↓56.8% | -35↓71.3% | -20 | |
| Income Tax Expense | -0.08↓127.8% | 0.29 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -171↓2241.8% | 8↑114.7% | -54↓56.8% | -35↓71.3% | -20 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -171↓2241.8% | 8↑114.7% | -54↓56.8% | -35↓71.3% | -20 | |
| Bottom-Line Net Income | -171↓2241.8% | 8↑114.7% | -54↓56.8% | -35↓71.3% | -20 | |
| EPS (Basic) | -1.74↓2209.1% | 0.08↑114.5% | -0.57↑34.5% | -0.87↓24.3% | -0.70 | |
| EPS (Diluted) | -1.74↓2327.9% | 0.08↑113.7% | -0.57↑34.5% | -0.87↓24.3% | -0.70 | |
| Weighted Average Shares | 99↑1.7% | 97↑1.8% | 95↑138.3% | 40↑38.4% | 29 | |
| Weighted Average Diluted Shares | 99↓3.7% | 102↑7.5% | 95↑138.3% | 40↑38.4% | 29 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.